Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia

Launched by RUHR UNIVERSITY OF BOCHUM · Feb 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying two common surgical procedures used to treat cervical dysplasia, which is a condition that can lead to cervical cancer if not treated. The trial specifically compares LLETZ (which removes a larger area of tissue including the affected zone) to LEEP (which focuses on the visible lesion only) to see which method is safer in terms of ensuring that all the dysplastic tissue is removed. The goal is to find the best approach for treating this condition to improve patient outcomes.

Women aged 65 to 74 who have been diagnosed with a specific type of cervical dysplasia (called High Grade Squamous Intraepithelial Lesion) and have a visible lesion may be eligible to participate. Participants in the study can expect to undergo one of the two procedures and will be monitored to evaluate the effectiveness and safety of the treatment. It’s important to note that women who are pregnant, on certain medications that weaken the immune system, or have other serious health conditions may not be eligible for the trial. Overall, this study aims to provide more information about the best surgical options for managing cervical dysplasia.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed High Grade Squamous Intraepithelial Lesion (HSIL)
• • Colposcopically visible lesion
• • No therapy of the disease so far
• Exclusion Criteria:
• • Pregnancy of the patient at/after inclusion in the study; pregnancy after conization and before the control after 6 months is possible and does not lead to exclusion from the study.
• • Taking immunosuppressive drugs (incl. glucocorticoids)
• • Known HIV positivity
• • Malignant disease requiring treatment
• • Unsatisfactory colposcopy